Filtros de búsqueda

Lista de obras de

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population

artículo científico publicado en 2010

A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers

artículo científico publicado en 2012

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

artículo científico publicado en 2001

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

artículo científico publicado en 2017

A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer

artículo científico publicado en 2016

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

artículo científico publicado en 2017

Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study

scientific article published on 01 April 2014

Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer

artículo científico publicado en 2002

Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer

artículo científico publicado en 2007

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

artículo científico publicado en 2017

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

artículo científico publicado el 3 de noviembre de 2010

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality

artículo científico publicado en 2010

Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers

artículo científico publicado en 2019

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2007

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers

artículo científico publicado en 2012

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2012

Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer

artículo científico publicado en 2006

Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine

artículo científico publicado en 2004

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2008

Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers

artículo científico publicado en 2011

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy

artículo científico publicado en 2007

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

artículo científico publicado en 2009

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer

artículo científico

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

artículo científico publicado en 2011

Evolutionary Pathways in BRCA1-Associated Breast Tumors ⬇️

artículo científico publicado el 10 de abril de 2012

Family environments of women seeking BRCA1/BRCA2 genetic mutation testing: an exploratory analysis

artículo científico publicado en 2004

Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.

artículo científico publicado en 2018

Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers

artículo científico publicado en 2011

Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers

artículo científico publicado en 2009

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities ⬇️

artículo científico publicado el 19 de noviembre de 2012

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

artículo científico publicado en 2015

Guidelines for systemic therapy of early stage breast cancer

artículo científico publicado en 1997

Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial

artículo científico publicado en 2017

Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil

artículo científico publicado en 2002

International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2013

Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes

artículo científico publicado en 2011

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers

artículo científico publicado en 2009

Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics.

artículo científico publicado en 2013

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

artículo científico publicado en 1999

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

artículo científico publicado en 2009

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

artículo científico publicado en 2001

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers

artículo científico publicado en 2010

Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2012

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

artículo científico publicado en 2019

POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer

artículo científico publicado en 2020

Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial

artículo científico publicado en 1996

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

artículo científico publicado en 2013

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

artículo científico publicado en 2015

Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ

artículo científico publicado en 2019

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

artículo científico publicado en 2009

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer

artículo científico publicado en 2005

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

scientific article published on 02 August 2010

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

artículo científico publicado en 2007

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer

scientific article published on 22 August 2006

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy

artículo científico publicado en 2007

Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer

artículo científico publicado en 2010

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

artículo científico publicado en 2006

Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer ⬇️

artículo científico publicado el 27 de octubre de 2012

Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

scientific article published on 01 September 2018

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

scientific article published on 28 October 2019

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study

artículo científico publicado en 2008

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

artículo científico publicado en 2018

Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

scientific article published on 25 November 2019

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

scientific article published on 20 August 2020

The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program

artículo científico publicado en 2016

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer

artículo científico publicado en 2008

The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy

artículo científico publicado en 2017

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

artículo científico publicado en 2014

Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis

artículo científico publicado en 2013

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer

artículo científico publicado en 2017

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2014

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations

artículo científico publicado en 2016

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

artículo científico publicado en 2003

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda